他唑巴克坦与哌拉西林联用的药理和临床

THE PHARMACOLOGICAL AND CLINICAL EVALUATION OF A COMBINED REGIMEN OF TAZOBACTAM/PIPERACILLIN

综述了他唑巴克坦／哌拉西林（ＴＡＺ／ＰＩＰＣ）的体外和体内抗菌作用、药代动力学及临床应用。他唑巴克坦是β－内酰胺酶抑制剂，ＴＡＺ与ＰＩＰＣ联合应用对各种产生β－内酰胺酶的细菌有协同抗菌作用。ＴＡＺ／ＰＩＰＣ对小鼠全身感染各种产酶细菌优于单用ＰＩＰＣ的效果。两药联合静注有良好药代动力学性能以及对各种实验动物未见明显药理影响，临床应用于各种感染性疾病，有效率为８５．５％。

The in vitro and in vivo antibacterial activities,pharmacokinetics,general pharmacology and clinical use of a combined regimen of tazobactam/piperacillin(TAZ/PIPC)are reviewed.Tazobactam,a new β lactamase inhibitor,when combined with piperacillin shows a synergistic antibacterial activity with a more potent theraputic effect than single PIPC in mice with systemic infection of β lactamase producing strains.TAZ/PIPC has a promising pharmacokinetic property and no significant pharmacological effect on experimental animals.It has clinically a effective rate of 85.5% for various infections with rare side effects.